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Abstract
Introduction: Glucosamine is an amino-monosaccharide and precursor of glycosaminoglycans, major components
of joint cartilage. Glucosamine has been clinically introduced for the treatment of osteoarthritis but the data about
its protective role in disease are insufficient. The goal of this study was to investigate the effect of long term
administration of glucosamine on bone resorption and remodeling.
Methods: The effect of glucosamine on bone resorption and remodeling was studied in a model of collagenase-
induced osteoarthritis (CIOA). The levels of macrophage-inflammatory protein (MIP)-1a, protein regulated upon
activation, normal T-cell expressed, and secreted (RANTES), soluble receptor activator of nuclear factor kappa-B
ligand (RANKL), tumor necrosis factor (TNF)-a, and interleukin (IL)-6, 4 and 10 in synovial fluid were measured by
enzyme-linked immunosorbent assay (ELISA). Cell populations in synovial extracts and the expression of RANKL, of
receptors for TNF-a (TNF-aR) and interferon g (IFN-gR) on clusters of differentiation (CD) three positive T cells were
analyzed by flow cytometry. Transforming growth factor (TGF)-b3, bone morphogenetic protein (BMP)-2,
phosphorylated protein mothers against decapentaplegic homolog 2 (pSMAD-2), RANKL and Dickkopf-1 protein
(DKK-1) positive staining in CIOA joints were determined by immunohistochemistry.
Results: The administration of glucosamine hydrochloride in CIOA mice inhibited loss of glycosaminoglycans
(GAGs) and proteoglycans (PGs) in cartilage, bone erosion and osteophyte formation. It decreased the levels of
soluble RANKL and IL-6 and induced IL-10 increase in the CIOA joint fluids. Glucosamine limited the number of
CD11b positive Ly6G neutrophils and RANKL positive CD3 T cells in the joint extracts. It suppressed bone
resorption via down-regulation of RANKL expression and affected bone remodeling in CIOA by decreasing BMP-2,
TGF-b3 and pSMAD-2 expression and up-regulating DKK-1 joint levels.
Conclusions: Our data suggest that glucosamine hydrochloride inhibits bone resorption through down-regulation
of RANKL expression in the joints, via reduction of the number of RANKL positive CD3 T cells and the level of
sRANKL in the joints extracts. These effects of glucosamine appear to be critical for the progression of CIOA and
result in limited bone remodeling of the joints.
Introduction
Glucosamine is one of the most abundant amino-mono-
saccharides immediately phosphorylated and included in
a hexosamine biosynthesis pathway. The end-product of
this pathway is UDP-N-acetylglucosamine, which is
important for the synthesis of glycoaminoglycans and gly-
colipids. Exogenous glucosamine is bound with high
affinity to glucose transporter GLUT-2 [1] and can
induce insulin resistance in adipocytes [2] and skeletal
muscle cells [3]. In joint and cartilage, glucosamine can
regulate the metabolism of glycosaminoglycans favoring
catabolic processes. Glucosamine expresses a number of
in vitro effects on chondrocytes, including stimulation of
proteoglycan synthesis, inhibition of proteoglycan and
collagen degradation, suppression of IL-1 induced activa-
tion and decrease of NF-B activity [4-8]. Glucosamine
has anti-inflammatory action suppressing inducible nitric
oxide synthase (iNOS) expression [9,10], neutrophil
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cells [12].
Glucosamine has been used for the treatment of
osteoarthritis (OA). It is administered in different phar-
macological forms, including sulfate, N-acetyl-glucosa-
mine, or chlorohydrate salt [13]. Oral application of
glucosamine is more frequent, but experimental data
about the effect of its intravenous injection have also
been performed [14]. Glucosamine is absorbed from the
gastrointestinal tract [15]. Depending on the pharmaco-
logical form used, its half-life in serum is from 28 h to
58 h [14]. Müller-Fassbender et al. have established that
glucosamine sulfate is as effective as ibuprofen in
patients with knee OA [16]. Long-term oral treatment
with this pharmacological form delayed the progression
and improved the symptoms of knee osteoarthritis act-
ing as a disease modifying agent [17]. In different trials,
it has been reported to exert improvement in OA [18],
h a v eam o d e r a t ee f f e c t[ 1 9 ]o rs h o wn od i f f e r e n c ew i t h
a placebo [20,21]. This variation in the results deter-
mines a need of more systemic investigations on the
mechanisms of glucosamine action.
OA develops as a result of an imbalance between bone
resorption and bone remodeling. Therefore, we have
conducted this study to evaluate the effect of glucosa-
mine on these processes mainly in the joint. Studies on
its systemic effects were not in the focus of our experi-
ments. Glucosamine was administered in an animal
model of OA. We determined the levels of pro- and
anti-inflammatory mediators and the phenotype of cells
in the synovial extracts as well as the expression of
resorption and remodeling markers in the joints.
Materials and methods
Mice
Outbred ICR (CD-2) male mice, 10- to 12-weeks-old,
weight 20 to 22 g, were purchased from the Charles
River Laboratories (Wilmington, MA, USA). Mice were
maintained on a 12:12 h light:dark cycle and fed stan-
dard diet and tap water ad libitum.A l le x p e r i m e n t s
were conducted in accordance with the Bulgarian
National Guidelines for the Care and Use of Laboratory
Animals (Decree No. 14/19.07.2000) and were approved
by the Animal Care Committee at the Institute of
Microbiology, Sofia.
Collagenase-induced osteoarthritis (CIOA) and treatment
For induction of OA, ICR male mice were injected at
right and left knee intra-articular (i.a.) space with 1 U/10
μlo rw i t h2U / 1 0μl of collagenase from Clostridium his-
tolyticum (Sigma-Aldrich, Diesenhofen, Germany) at days
0 and 2. The incidence of OA was approximately 90%.
A study to compare the development of CIOA in male
and female animals was not conducted. Control group of
animals received i.a. injection of 10 μle n d o t o x i n - f r e e
phosphate-buffered saline (PBS; Lonza, Verviers,
Belgium).
D(+)-glucosamine hydrochloride (Glu) and D-glucosa-
mine 2-sulfate sodium salt (GS) purchased from Sigma-
Aldrich (Munich, Germany) were dissolved in sterile
PBS and were administered orally by gavage at a dose of
20 mg/kg/daily. Two groups were treated with Glu
(CIOA + Glu1) or GS (CIOA + GS) for 20 days, starting
from Day 7 after the second collagenase injection and a
group of mice with arthritis were fed with PBS (CIOA).
Control groups of mice were i.a. injected with PBS and
were untreated (healthy) or treated with glucosamine
hydrochloride (healthy + Glu). One group of mice was
treated with Glu for 20 days starting with the second
collagenase injection (CIOA + Glu2). In another experi-
mental setting CIOA was induced after injection of a
higher dose of collagenase (2 U/mouse at Day 0 and at
Day 2). The oral administration of glucosamine hydro-
chloride started 7 days after the second collagenase
injection and lasted 20 days.
Synovial extracts
Patellae with surrounding soft tissue (tendon and syno-
vium) were excised, and incubated in 200 μl of serum-free
RPMI 1640 medium (Biowhittaker™,L o n z a ,V e r v i e r s ,
Belgium) for 2 h at 37°C as described by van de Loo et al.
[22]. The washouts were collected separately for each ani-
mal and centrifuged at 1,200 × g for 10 minutes. Superna-
t a n t sw e r es t o r e da t- 7 0 ° Ca n du s e df o rc y t o k i n ea s s a y s .
Synovial cells were counted and used for flow cytometry
analyses.
Determination of chemokines and interleukins in synovial
extracts
The amounts of MIP-1a, RANTES, soluble RANKL,
TNF-a, IL-6, IL-4 and IL-10 in synovial extracts were
determined by ELISA using mouse ELISA kits. The
samples were assayed in triplicates. The concentration
of chemokines and cytokines was calculated from a
standard curve of the corresponding recombinant
mouse protein, using Gen5 Data Analysis Software (Bio-
Tek Instruments, Bad Frienarichsall, Germany) and was
presented in pg/ml supernatant. ELISA kits were with
detection limits 8 pg/ml for MIP-1a,1 6p g / m lf o r
R A N T E S ,6 2p g / m lf o rR A N K L ,3 2p g / m lf o rT N F - a,
20 pg/ml for IL-6, 20 pg/ml for IL-10 (all from Pepro-
Tech EC, London, UK) and 10 pg/ml for IL-4 (BD Phar-
mingen, Erembodegem, Belgium).
Isolation of peripheral blood mononuclear cells (PBMCs)
Blood was collected by retro-orbital puncture in tubes
containing 5 U/ml of heparin. Blood was mixed with
an equal volume of PBS (pH 7.4). After gradient
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1,400 × g for 40 minutes at room temperature, periph-
eral blood mononuclear cells (PBMCs) were carefully
collected, washed with PBS, counted and used for flow
cytometry analyses.
Flow cytometry
Synovial extract cells and peripheral mononuclear cells
were resuspended at 2 × 10
5/ml in PBS containing 2%
fetal calf serum (FCS). The cells were incubated for
15 minutes at 4°C with appropriately diluted antibodies
from BD Pharmingen (Erembodegem, Belgium) against
mouse Ly-6G (FITC-conjugated; clone RB6-8C5),
CD11b (PE-conjugated; clone M1/70), CD69 (APC-con-
jugated, clone H1.2F3) and CD3 (FITC or PE conju-
gated, clone 145-2C11) washed and used in flow
cytometry.
For determination of TNF-aR, IFN-gRa n dR A N K L
expression, synovial cells and PBMCs were incubated
for 30 minutes at 4°C with biotinylated antibodies
against mouse TNF-aR1 (2 μg/ml; clone H-271; Santa-
Cruz Biotechnology Inc., Heidelberg, Germany), IFN-
gRa (5 μg/ml; clone M-20; Santa-Cruz Biotechnology)
and RANKL (1 μg/ml, PeproTech EC) or with isotype
controls (Sigma-Aldrich). After washing with 2% FCS/
PBS, secondary avidin-FITC (4 μl/sample, Becton Dick-
inson, San Jose, CA, USA) was added for 15 minutes at
4°C. After four times washings with PBS, the samples
were analyzed by a flow cytometer (BD™LSR II) using
FCS Express™Diva Software (Becton Dickinson, San
Jose, CA, USA).
Histological analyses
Dissected ankle joints were fixed in 10% paraformalde-
hyde/PBS, decalcified in 5% nitric acid for one week,
dehydrated and embedded in paraffin. Sections (6 μm
thickness, rotary microtome Accu-Cut
® SRM™ Sacura
Finetek, Tokyo, Japan) were stained with hematoxylin
and eosin (H&E), toluidine blue or safranin O/fast
green. Images were captured with a coupled device cam-
era and exported to Adobe Photoshop 7.0 (Adobe Sys-
tems, Munich, Germany). The joint damage was scored
using the semi-quantitative grading and staging system
[23]. The severity of damage was graded from 0 (normal
joint architecture) to 6 (deformation, joint margin osteo-
phytes formation and bone remodeling). The extent of
the damage reflecting OA stage was scored from 0
(whole cartilage surface intact) to 4 (more than 50% of
cartilage surface affected). The histological score of joint
damage was obtained after multiplying the grade and
stage scores (maximum score 24). Captured images of
t h ej o i n t sw e r ee x a m i n e df o rt h ep r e s e n c eo fo s t e o -
phytes. The osteophyte area was measured using ima-
ging system software (ImageJ 1.42; Research Services
Branch, NIH, Bethesda, Maryland, USA) and an average
value of five joint sections per group was calculated.
Immunohistochemistry
The sections (6 μm) were permeabilized with 0.1% Tri-
ton X-100 in PBS for 20 minutes, washed with PBS and
blocked with 5% bovine serum albumin/PBS for 1 h at
room temperature. The endogenous peroxidase was
blocked by 0.3% H2O2 in 60% methanol for 10 minutes.
After washing, the sections were incubated for 40 min-
utes at room temperature with antibodes against
RANKL (50 μg/ml; PeproTech EC), BMP2 (0.1 μg/ml),
TGF-b3( 1 0μg/ml), pSMAD-2 (20 μg/ml) and DKK-1
(10 μg/ml; all from Abcam, Cambridge, UK). Isotype
antibodies (anti-mouse IgG or anti-rabbit IgG; Sigma-
Aldrich) were used as a background staining control.
After washing, the joint sections were incubated for
10 minutes with biotinylated anti-mouse or anti-rabbit
IgGs (Abcam). Then streptavidin-peroxidase (1:100
diluted; Abcam) was added for 10 minutes. The sections
were washed and incubated with DAB solution kit
(3’,3’diaminobenzididne kit, Abcam) for 10 minutes and
counterstained with Gill’s hematoxylin for 3 minutes.
The number of cells stained positive for the examined
proteins was determined by imaging system software
(ImageJ 1.42; Research Services Branch, NIH, USA).
Statistical analyses
Statistical analyses were performed using InStat3.0 and
GraphicPad Prism 5.0 (GraphPad Software Inc., La Jolla,
CA, USA). Data are expressed as mean ± standard
deviation (SD). The histological score data and the
immunohistochemistry data were analyzed using the
Mann-Whitney U-test. For other data, the differences in
mean values between groups were analyzed by two-
tailed Student’s t-test. Differences were considered sig-
nificant when P < 0.05.
Results
Cytokine levels in the synovial extracts at Day 7 of CIOA
At Day 7 of CIOA, we found high levels of pro-inflam-
matory mediators MIP-1a, RANTES, soluble RANKL,
TNF-a and IL-6 in the synovial extracts. The levels of
anti-inflammatory cytokines IL-4 and IL-10 were nearly
undetectable similarly to healthy mice (Table 1).
Effect of glucosamine on the development of CIOA
The severity and progression of CIOA was evaluated by
scoring the histological changes in the joints (grade) and
the extent of cartilage involvement in these changes
(stage of CIOA). The repeated injection of 1 U/mouse
of collagenase resulted in cartilage erosion and matrix
loss. Histological analyses of H&E stained sections of
CIOA joints showed matrix cracks and fissures extended
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vation and cartilage fractures. Reduced density of Tolui-
dine blue staining in CIOA mice demonstrated marked
loss of glycosaminoglycans (GAGs) in the cartilage
(Figure 1b). Safranin O staining showed significant
proteoglycan depletion in CIOA joints (Figure 1c). In
several CIOA joints we were able to detect osteophyte
areas indicative of bone repair processes, initiated as a
result of severe cartilage and matrix loss (Figure 1d). All
together our data showed the development of moderate
Table 1 Chemokine and cytokine levels in the joint extracts on Day 7 of CIOA
Cytokines (pg/ml)
Groups MIP-1a RANTES sRANKL TNF-a IL-6 IL-4 IL-10
Healthy 30 ± 10 <16 <62 32 ± 20 <62 <10 28 ± 12
CIOA 720 ± 55*** 320 ± 24*** 300 ± 70*** 760 ± 56*** 540 ± 68*** 28 ± 16 38 ± 10
Mice (n = 15 in each group) were injected i.a. with 1 U/mouse of collagenase on Day 0 and Day 2. Synovial extract was collected separately from each animal at
Day 7 of CIOA and the level of several mediators was determined by ELISA; Student’s t-test; ***P < 0.001 vs healthy mice.
CIOA, collagen-induced osteoarthritis; ELISA, enzyme linked immunosorbent assay; IL, interleukin; MIP-1a, macrophage inflammatory protein 1a; sRANKL, soluble
receptor activator of nuclear factor kappa B ligand; RANTES, regulated upon activation, normal T-cell expressed, and secreted protein; TNF, tumor necrosis factor.
Figure 1 Effect of glucosamine on the development of CIOA. CIOA was induced by injection of 1 U/mouse collagenase at Day 0 and Day 2.
After seven days, CIOA mice were orally treated with PBS (CIOA; n = 15), with glucosamine hydrochloride (20 mg/kg/daily; CIOA + Glu1; n = 15)
or glucosamine sulfate (20 mg/kg/daily; GS, n = 10) for 20 days, or with glucosamine hydrochloride (20 mg/kg/daily) started with the second
collagenase injection and lasted 20 days (20 mg/kg/daily; CIOA + Glu2; n = 10). A control group of non-arthritic mice were fed with PBS
(healthy; n = 9). (a) Representative joint sections stained with H&E showed fissures and fractures in cartilage and bone matrix of CIOA mice at
Day 30, attenuated by Glu1 and Glu2, but not by GS; magnification × 40. Staining with Toluidine blue (b) and Safranin O (c) demonstrated GAGs
and PG loss in CIOA that was less pronounced in Glu1-treated CIOA mice; magnification × 100. Glu1 and Glu2 significantly reduced the
osteophyte areas in CIOA mice, while GS was not effective (d). Data are expressed as the mean ± SD from the evaluation of five joint sections/
group; Student’s t-test; **P <0.01 vs CIOA group. (e) Glu1 and Glu2 significantly decreased the total histological score in CIOA mice and
nonsignificantly by GS. Total histological score was calculated using the semi-quantitative grading and staging system. Data are expressed as the
mean ± SD from the evaluation of 10 joints/group; Student’s t-test; ***P <0.001 vs CIOA group.
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4.5 (n = 15, Figure 1e).
CIOA mice were treated with glucosamine hydro-
chloride for 20 days, starting with (Glu2) or 7 days after
the second collagenase injection (Glu1). The administra-
tion of the drug under two different schedules (Glu1
and Glu2) had a beneficial effect on the development
and progression of CIOA as demonstrated by inhibited
joint damages (Figure 1a) and reduced total histological
score (Figure 1e). Mice treated with Glu1 showed less
exerted bone erosion, matrix fissures, GAG and PG loss
(Figure 1b, c), and osteophyte areas (Figure 1d). The
administration of GS under the schedule of Glu1 group
for 20 days did not inhibit cartilage erosions, matrix loss
and osteophyte formation (Figure 1a) and failed to
improve histological signs of disease (Figure 1e).
In another set of experiments glucosamine hydro-
chloride was administered after Day 7 of injection with
a higher dose of collagenase (2 U/mouse at Day 0 and
at Day 2). The treatment lasted 20 days (Figure S1b in
Additional file 1). At Day 30 all CIOA joints showed
bone remodeling and repair with extensive osteophyte
and fibrocartilage formation, denudation, deformation of
articular surface and changes in the joint architecture
(Figure S1a in Additional file 1). A high histological
score of 22.3 ± 5.2 (maximum 24) demonstrated the
development of severe OA. The administration of gluco-
samine decreased osteophyte and fibrocartilage areas in
CIOA joints, although this effect did not reach statistical
significance and was observed for some but not for all
joint sections (Figure S1b in Additional file 1).
Glucosamine altered the chemokine and interleukin
secretion in the synovial extract of CIOA mice
Several cytokines can affect the severity and progression
of OA. We evaluated the level of MIP-1a,R A N T E S ,
TNF-a, soluble RANKL, IL-10 and IL-4 in the synovium
extracts on Day 30 of CIOA (Figure 2). In healthy mice
the presence of all mediators was in negligible amounts
similar to the group of non-arthritic mice, treated with
Glu1 except for IL-10, whose level was elevated.
Increased levels of MIP-1a, RANTES, TNF-a,s o l u b l e
RANKL and IL-10 were established in CIOA mice. Glu-
cosamine markedly enhanced IL-10 in the joint extracts,
while MIP-1a,R A N T E Sa n dT N F - a were not affected.
The administration of the drug for seven days (or Day
14 of CIOA, insert in Figure 2) significantly decreased
soluble RANKL. Low levels of sRANKL were also
detected after long term treatment (20 days) of CIOA
mice with glucosamine (Figure 2). In ongoing OA
(insert Figure 2), the drug did not affect the level of
IL-6, but was able to reduce it after prolonged adminis-
tration (20 days; Figure 2).
Glucosamine decreased the number of Ly6G neutrophils
and CD3 T cells in the synovial extract
We performed flow cytometry analyses of synovial cells
for the surface expression of CD3, CD69, Ly6G and
CD11b. At Day 30 of CIOA around 30% of synovial
cells expressed neutrophil marker Ly6G, significantly
reduced in Glu1 and GS-treated groups (Figure 3a). Low
frequencies of single CD11b cells were found in GS and
Glu1-treated groups (Figure 3b). CD3 expressed on 19%
of synovial CIOA cells was greatly reduced by Glu1 and
more slightly by GS (Figure 3c). Similar tendency was
observed in regard to double positive CD3+/CD69+
cells. The number of activated cells (3%) was decreased
in the synovial extracts of Glu1- and GS-treated groups
(Figure 3d).
Glucosamine changed the expression of TNF-aR and IFN-
gR on synovial CD3 T cells
Synovial extracts from CIOA mice contained CD3 posi-
tive T cells that can respond to pro-inflammatory cyto-
kines like TNF-a and IFN-g after engagement of the
particular receptor. Thus, we next evaluated the expres-
sion of TNF-aRa n dI F N - gRo nC D 3Tc e l l s .I no r d e r
to perform correct flow cytometry analyses, the expres-
sion of both receptors was evaluated within gated CD3
positive cell population in all groups (Figure 4). In
healthy mice synovial CD3 T cells expressed TNF-aR1
(mean expression of 1,006 ± 345), while CIOA mice
showed low surface expression of the receptor (mean
expression of 95 ± 12). In glucosamine-treated mice
with CIOA TNF-aR1 expression was comparable to
that in healthy mice (mean expression of 915 ± 102)
(Figure 4a). Opposite to these findings, we observed low
expression of IFN-gR1 on CD3 T cells in healthy mice.
The surface expression of IFN-gR1 increased in CIOA
mice (mean expression of 1,496 ± 213) which was
down-regulated by glucosamine (mean expression of
595 ± 87) (Figure 4b).
Effect of glucosamine on the percentage of RANKL
positive synovial and peripheral CD3 T cells
In the next experiments synovial CD3 T cells were sub-
jected to flow cytometry analysis for RANKL expression.
At Day 30 of CIOA, almost all CD3 positive cells
expressed RANKL (15.4%; Figure 5a). Glucosamine sig-
nificantly reduced the number of RANKL positive syno-
vial CD3 T cells (Figure 5b). In the periphery CD3 T
cells in all experimental groups were around 55% of
total cell population (healthy mice - 50.2 ± 10.2; CIOA
mice - 57.3 ± 15.4 and CIOA+Glu - 60.0 ± 6.2). In
CIOA only 1.6% of peripheral CD3 T cells were RANKL
positive compared to 19.6% in healthy mice and 24.1%
in glucosamine-treated group (Figure 5c). Glucosamine
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to the values observed in healthy mice (Figure 5d).
Effect of glucosamine on the expression of markers for
bone erosion and remodeling
The progression of OA is often due to the lack of bal-
ance between bone resorption and formation. We next
evaluated the expression of RANKL, a molecule charac-
teristic for bone resorption and of BMP2, TGF-a3,
pSMAD-2 and DKK-1, molecules indicative for bone
repair and remodeling. The expression of these markers
i nt h ej o i n t si ss h o w ni nF i g u r e6a n dT a b l e2 .W e
found single RANKL positive cells in healthy mice. High
RANKL expression was determined at Day 30 of CIOA
and in all joint sections with extensive bone erosion.
Glucosamine reduced significantly RANKL positive cells
in CIOA joints (Figure 6a, Table 2). The direct action of
glucosamine on osteoclasts was determined in vitro.
Bone marrow cells were differentiated with M-SCF and
RANKL in the presence of increasing concentrations of
t h ed r u g .G l u c o s a m i n ei n h i b ited in a dose-dependent
manner osteoclast differentiation (Figure S2 in Addi-
tional file 2). Immunohistochemistry analysis demon-
strated BMP-2 staining of osteophyte areas in CIOA
joints that was exerted less in glucosamine-treated
group (Figure 6b, Table 2). TGF-a3 positive cells were
increased in cartilage of CIOA mice compared to
healthy and glucosamine fed mice (Figure 6c). Down-
stream signaling of TGF-a3 involved phosphorylation of
SMAD-2. The positive staining for pSMAD-2 found in
cartilage of healthy mice was two-fold greater in CIOA
joints. Glucosamine down-regulated the expression
of pSMAD-2 (Figure 6d, Table 2). Another protein
involved in bone formation is DKK-1, a specific mole-
cule that blocks Wnt signaling. Expression of DKK-1
was observed in healthy mice. The number of DKK-1
positive cells decreased at Day 30 of CIOA indicating a
loss of regulatory signal to Wnt pathway in favor of
bone formation. In the group of glucosamine-treated
CIOA mice we were able to detect DKK-1 positive cells
not significantly different from healthy mice (Figure 6e,
Table 2).
Discussion
Glucosamine is an agent that improves functional activity
and slows the progression of OA especially of the hip and
knee. Most of the clinical studies with glucosamine,
designed to treat OA have shown good or moderate symp-
tomatic efficacy [20,24-26]. Contradictory results have
been observed regarding the effectiveness of glucosamine
on pain and disability in OA patients vs placebo patients
[27,28]. Such discrepancy is due to the use of different for-
mulations, as hydrochloride or sulfate salts are claimed to
have various efficacies. Additionally, the interpretation of
Figure 2 Effect of glucosamine on the synovial level of soluble RANKL, IL-6 and IL-10. Joint extracts were collected from individual mice
treated with PBS (healthy, n = 9), non-arthritic mice treated with glucosamine hydrochloride for 20 days (20 mg/kg/daily; healthy + Glu, n = 10),
CIOA mice (n = 15) and CIOA mice treated with glucosamine hydrochloride for 20 days, starting from Day 7 (20 mg/kg/daily; CIOA + Glu1; n =
15). The levels of particular cytokine (MIP-1a, RANTES, soluble RANKL, TNF-a, IL-6, IL-4 and IL-10) on Day 14 (insert) and on Day 30 of CIOA were
determined by ELISA and expressed as picograms/ml supernatant. Data represent the mean ± SD of two independent experiments involving
from 9 to 15 animals/group; *P < 0.05; ***P < 0.001 CIOA vs CIOA+Glu1;
###P < 0.001 vs healthy. Student’s t-test.
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tion and in the cohort studied. Chemically and structurally
chloride and sulfate are identical and the nature of the
included salt should not influence their biological effect.
Glucosamine hydrochloride has no beneficial effect in
regard to relieving OA pain and disability but the lack of
histological data prevents firm conclusions about its effect
on other disease symptoms [29]. Our histological data
showed that glucosamine sulfate was less effective than
glucosamine hydrochloride when both were administered
under the same conditions in CIOA.
In the present study, the CIOA animal model has
been chosen as relevant to the pathology of OA patients
and the oral route as relevant to the clinical application
of glucosamine. We compared two schedules for 20-day
treatment with glucosamine hydrochloride, starting with
the injection of collagenase or seven days thereafter
(ongoing OA). In ongoing OA (Day 7) chemokines and
cytokines were elevated in the synovium and histological
signs of cartilage damage were already registered. On
Day 30 the disease was defined as moderate OA, charac-
terized by cartilage erosion, matrix loss, GAG and PG
Figure 3 Phenotype of cells in the synovial extract at Day 30 of CIOA. Joint extracts were collected from mice treated with PBS (healthy, n
= 5), nonarthritic mice treated with glucosamine hydrochloride for 20 days (20 mg/kg/daily; healthy + Glu, n = 5), CIOA mice (n = 5) and CIOA
mice treated with of glucosamine hydrochloride for 20 days, starting from Day 7 (20 mg/kg/daily; CIOA + Glu1; n = 5) or with GS (20 mg/kg/
daily; CIOA + GS, n = 5). Samples were obtained separately from each mouse. Individual data were presented in dot-plot graphs. The median
value is shown in the graphs with line. *P < 0.05; **P < 0.01; ***P < 0.001 vs healthy;
###P < 0.001 vs CIOA group;
++P < 0.01;
+++P < 0.001 CIOA
+ Glu1 group vs GS. Student’s t-test.
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demonstrated that glucosamine ameliorated the degree
of joint damage. Lower histological score in glucosa-
mine-treated CIOA group was related to inhibited bone
erosion, as shown by reduced GAG and PG loss, and
limited areas of bone outgrowth at the edges of the
joints.
However, limited numbers of investigations have
demonstrated the precise mechanism of glucosamine
action in OA. In this study the experiments were
focused on the events in the joint without detailed
assessment of the systemic action of glucosamine. In rat
non-arthritic models the drug showed anti-inflammatory
action by suppressing iNOS protein expression in the
spleen, lung and peritoneal macrophages [10]. Yet, glu-
cosamine might have systemic action, in that it also sup-
presses nuclear factor kappa B activity [30]. Particularly,
this pathway is blocked in chondrocytes cultured in the
presence of glucosamine, suggesting that it may sup-
press inflammatory signaling [7]. Cytokines and growth
factors play an important role in the pathology of OA
[31,32]. They are produced by the synovial cells, chon-
drocytes and inflammatory cells, and later, diffuse to the
cartilage through the synovial fluid. Does glucosamine
act on the inflammatory mediators in the synovium? On
D a y3 0w eo b s e r v e di nC I O Am i c eh i g hs y n o v i a ll e v e l s
of the pro-inflammatory cytokine TNF-a and elevated
levels of chemokine RANTES (CCR5) and chemoattrac-
tant protein MIP-1a, an indication of persistent local
inflammation. During ongoing OA, glucosamine was not
able to reduce the production of MIP-1a,R A N T E Sa n d
TNF-a. After seven-day treatment we observed that
sRANKL level in the synovium was lowered compared
to untreated mice, but the IL-6 level was not affected.
The substance, however, significantly lowered the level
of soluble RANKL and IL-6, and increased the level of
IL-10 in the joint on Day 30. This shows that various
mediators play different roles through the course of the
disease. RANKL is a ligand for RANK expressed on
osteoclast precursors. RANKL-RANK interaction trig-
gers the activation of NF-kB and AP-1 transcription fac-
tors that drives osteoclast differentiation [33]. While IL-
10 directly inhibits RANKL-induced osteoclastogenesis
[ 3 4 ] ,I L - 6p l a y sam o r ec o m p l e xa n dd u a lr o l ei nt h i s
process. IL-6 can suppress bone resorption by inhibiting
the differentiation of osteoclast progenitors [35] and by
down-regulating RANK expression on mature osteo-
clasts [36]. When IL-6 is at a high level, it binds to solu-
ble IL-6R and can directly induce RANKL expression on
osteoblasts [37] and on synovial fibroblasts that favor
bone resorption [38]. In glucosamine-treated mice the
reduction of IL-6 and the increase of IL-10 levels can
inhibit the expression of RANKL in the joints. We
found only a few RANKL-positive chondrocytes and
synoviocytes in cartilage of glucosamine-treated CIOA
mice. In vitro experiments showed that glucosamine
dose-dependently inhibited osteoclast differentiation of
bone marrow cells. The membrane-bound RANKL is
expressed as a trimeric transmembrane protein [39], as
a truncated ectodomain cleaved by TNF-a convertase
and matrix metalloproteinase 14 [40,41] and as a pri-
mary secreted form, produced by activated T cells [42].
Figure 4 Glucosamine up-regulated TNF-aR1 and down-regulated IFN-gR1 expression in CIOA on synovial CD3 T cells. Synovial cells
were obtained at Day 30 from joint extracts of healthy (n = 5) mice, CIOA mice treated with PBS (CIOA; n = 5) and CIOA mice treated with
glucosamine (CIOA + Glu1, n = 5). Synovial cells were stained with PE-labeled antibody against CD3 and with biotinylated antibodies against
TNF-aR1 and IFN-gR1 followed by avidin-FITC staining and were subjected to flow cytometry. Data represent the mean of fluorescence
expression ± SD from two independent experiments involving five mice/group; Student’s t-test; ***P < 0.001.
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Page 8 of 13Our data showed that glucosamine inhibited the expres-
sion of RANKL in the joints and also reduced the level
of sRANKL in synovial extract of CIOA mice. Soluble
RANKL directly participate in bone erosion through its
excess production by activated CD3 and CD4 cells
in synovial fluid in RA patients [43]. Thus, we can
hypothesize that diminished levels of sRANKL can be
responsible for suppressed bone erosion in glucosamine-
treated CIOA mice. If OA develops as a result of an
imbalance between bone resorption and bone remodel-
ing, the question arises whether glucosamine can influ-
ence another remodeling marker besides RANKL.
In established CIOA, we found intensive formation of
osteophytes indicating a prevalence of bone remodeling.
It is reported that cartilage damage is highly associated
with the presence of osteophytes [44], which can be the
source of pain and disability in OA [45]. It is not exactly
known whether they are formed as a way to compensate
for the instability of destructed bones or as a result of
extensive local production of growth factors [46]. We
observed that glucosamine inhibited the formation of
osteophytes in CIOA joints. Simultaneously, we found
fewer osteophyte areas positive for BMP-2 in the gluco-
samine-treated group. BMP-2, a member of the TGF-b
family, can induce osteophyte formation [47] and is
expressed at a late stage of endochondral ossification
[48,49]. The reduced BMP-2 expression in glucosamine-
treated CIOA mice showed that bone remodeling is
initiated but does not progress. Thus, we evaluated the
expression of another factor that can induce osteophyte
formation, TGF-b3, which appears earlier than BMP2 in
osteophytes [50]. Increased numbers of cartilage cells
positive for TGF-b3 were found at Day 30 of CIOA.
TGF-b3 signaling was active since phosphorylation of
downstream molecule SMAD-2 was also detected in the
CIOA joints. Davidson et al.h a v es h o w nt h a tT G F - b3
Figure 5 Effect of glucosamine on the percentage of RANKL positive synovial and peripheral CD3 T cells. Synovial cells and PBMCs were
obtained at Day 30 from healthy (n = 5) mice, CIOA mice treated with PBS (CIOA; n = 5) and CIOA mice treated with glucosamine hydrochloride
(CIOA + Glu1, n = 5). The cells were stained with PE-labeled antibody against CD3 and with biotinylated antibody against RANKL followed by
avidin-FITC staining and were subjected to flow cytometry (a) Representative data showing the inhibitory effect of glucosamine on the number
of RANKL positive synovial CD3 T cells, (b) Glucosamine suppressed the RANKL expression of synovial CD3 T cells. Data represent the mean of
positive cells ± SD from two independent experiments involving five mice/group; Student’s t-test; ***P < 0.001, (c) Representative data showing
increased percentage of RANKL positive peripheral CD3 T cells in glucosamine-treated CIOA mice, (d) Glucosamine increased the RANKL
expression of peripheral CD3 T cells. Data represent the mean of positive cells ± SD from two independent experiments involving five mice/
group; Student’s t-test; **P < 0.01, ***P < 0.001.
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Page 9 of 13and pSMAD-2 expression in cartilage decreased with
the progression of a collagenase-induced model of OA
and is absent at late stages of severe OA [50]. Such dif-
ferent TGF-b3 and pSMAD-2 expression were observed
in moderate and severe OA induced with different doses
of collagenase. The injection of 1 U/mouse resulted in
OA with signs of bone erosion and expression of TGF-
b3 on cartilage cells. When severe OA is induced by
repeated injection of 2 U/mouse (Figure S1 in Addi-
tional file 1) we were not able to detect TGF-b3a n d
pSMAD-2 positive cells in the joints, confirming the
observations of Davidson et al.[ 5 0 ] .D o w n - r e g u l a t e d
TGF-b3 and pSMAD-2 expression on cartilage cells
may contribute to inhibited chondrogenesis, altered
chondrocyte terminal differentiation and/or reduced
hypertrophy of chondrocytes. In severe OA, the admin-
istration of glucosamine was neither able to affect TGF-
b3 signaling in cartilage nor to inhibit bone remodeling
and osteophyte formation. The data indicated that fac-
tors other than TGF-b3 and pSMAD-2 can become
important in bone remodeling and repair at Day 30 of
CIOA, probably BMP-2.
Wnt signaling is a key factor involved in bone forma-
tion. Wnt proteins enhance osteoblast differentiation
and inhibit osteoclast formation [51-53]. DKK-1 is a
negative regulator of Wnt signaling [54]. Heterozygous
DKK-1(+/-) mice had increased number of osteoblasts
and high rates of bone turnover [55]. In CIOA mice low
expression of DKK-1 in the joint indicated increased
activation of Wnt signaling in favor of bone formation.
DKK-1 staining was more pronounced in glucosamine-
treated CIOA mice suggesting an increase of bone
Figure 6 Glucosamine altered the expression of bone resorption and bone remodeling markers in the CIOA joints. Joints of healthy
mice, CIOA mice treated with PBS (CIOA) and CIOA mice treated with glucosamine hydrochloride (CIOA + Glu1) were fixed, decalcified,
dehydrated and embedded in paraffin. The sections (n = 10/mice) were stained with antibodies against RANKL, BMP-2, TGF-b3, pSMAD-2 and
DKK-1. The specific staining was detected using a peroxidase-DAB staining kit. The positive staining for RANKL in the joints (a), BMP-2 in
osteophyte areas (b) and TGF-b3 (c), pSMAD-2 (d) and DKK-1 (e) in cartilage of CIOA mice untreated or treated with glucosamine was indicated
with arrows; magnification × 100.
Table 2 Number of cells stained positive in CIOA joints
on Day 30
Bone markers
Groups RANKL BMP2 TGF-b3 pSMAD2 DKK1
Healthy 5 ± 1 nd 109 ± 12 18 ± 3 75 ± 12
CIOA 65 ± 12 136 ± 21 145 ± 22 36 ± 6 32 ± 9
CIOA+Glu1 8 ± 1*** 102 ± 10* 112 ± 14* 12 ± 3*** 89 ± 13***
Joint sections were obtained and stained as described in Figure 6. The
number of positive cells was evaluated by a computerized imaging system.
Data represent the mean of positive cells ± SD from two independent
experiments involving five mice/group (10 joint sections/mice); nd, not
detectable; Mann-Whitney U-test; *P < 0.05, ***P < 0.001 vs CIOA group.
BMP, bone morphogenetic protein; CIOA, collagen-induced osteoarthritis;
DKK1, Dickkopf-1; Glu, glucosamine hydrochloride; pSMAD-2, phosphorylated
protein mothers against decapentaplegic homolog 2; RANKL, receptor
activator of nuclear factor kappa B ligand; SD, standard deviation; TGF,
transforming growth factor.
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Page 10 of 13resorption. Pro-inflammatory mediators like TNF-a can
enhance DKK-1 expression [56]. However, glucosamine
was not able to change the level of TNF-a in synovial
fluid of CIOA mice. Probably, a complex interplay
between osteoclasts and osteoblasts can explain this
finding. DKK-1 can regulate osteoclastogenesis by
enhancing RANKL/RANK interactions and by down-
regulating osteoprotegerin secretion [53,57]. Thus,
increased DKK-1 in the glucosamine-treated group can
be a mechanism that prevents excessive bone formation
in CIOA mice.
The perpetuation of the inflammatory response in
CIOA is related to elevated numbers of cells in synovial
extracts and particularly to influx of neutrophils. Hua et
al. showed that glucosamine had a direct effect on neu-
trophil function. It inhibited superoxide generation and
phagocytosis of neutrophils, and also can suppress for-
myl-Met-Leu-Phe-induced up-regulation of CD11b on
these cells [11]. When coupled to FcgRs, CD11b can
trigger p38 mitogen-activated protein kinase pathways,
important for actin polymerization and chemotaxis of
neutrophils [58]. A recent study has shown that neutro-
phils expressed RANKL [59] and can activate directly
osteoclasts in a coculture system [60]. Glucosamine via
inhibition of neutrophil chemotaxis to synovium can
have an impact on osteoclastogenesis and bone destruc-
tion. CD11b is also expressed on monocytes, cells that
are the source of osteoclast precursors. An inhibited
number of CD11b positive cells in the synovial extracts
from glucosamine-treated mice can result in reduced
numbers of osteoclast precursors and in turn, in
restricted osteoclastogenesis. The role of T cells in the
pathology of OA should not be neglected as T cell infil-
trates are frequently detected in the synovial membrane
of patients with OA [61]. In CIOA mice we found an
increased percentage of cells expressing CD3 (18%).
However, only 3% of them were activated and expressed
CD69. CD3 T cells showed low TNF-aR expression,
even lesser than that on CD3 cells from healthy mice,
while they were highly positive for RANKL. Recently, it
has been shown that TNF-aR plays an important role in
RANKL signaling, since it can compete with RANKL for
the intracellular molecules TNF receptor associated fac-
tors 2, 5, and 6 [62]. When more TNF-aRs are engaged,
RANKL signaling is less sensitive and expression of
RANKL decreased. In support to this finding, we have
observed up-regulation of TNF-aR but inhibited
RANKL expression on synovial CD3 T cells from gluco-
samine-treated CIOA mice. RANKL-positive CD3 T
cells in synovium can interact with osteoclasts, dendritic
cells and/or neutrophils, all expressing RANK and thus,
promoting local pro-inflammatory response and bone
resorption. While glucosamine treatment reduced the
number of synovial RANKL positive cells, such a
reduction was not observed in the periphery. Probably,
fewer RANKL-positive CD3 T cells infiltrate CIOA
joints and thus, more of them were found in the periph-
ery. Recently, it has been demonstrated that the recruit-
ment of IFN-gR1 into the immunologic synapses of
helper T (Th) cells correlates with their capacity to dif-
ferentiate into Th1 effector cells [63]. In our study, glu-
cosamine inhibited the expression of IFN-gR1 on CD3 T
cells suggesting that the drug can have an impact on
Th1 cell differentiation and on the perpetuation of
inflammatory processes in OA. Histologically, in the OA
synovium a mixed inflammatory infiltrate consisting
mainly of macrophages is observed [64]. OA synovial
macrophages exhibit an activated phenotype and they
mediate osteophyte formation and other OA-related
pathology [65]. It is an important question: Which cell
type in the OA synovium is predominantly affected by
glucosamine? In order to answer the question further
experiments should be conducted, possibly by depletion
of neutrophils, macrophages or CD3 cells.
Conclusions
Our data show that glucosamine acted on the arthritic
process in joints through inhibition of neutrophils and, at
least, partially of T cells, particularly of CD3. The sub-
stance attenuates bone resorption in moderate OA via
inhibition of RANKL expression in the joint, reduction of
sRANKL and IL-6 levels, and increase of IL-10 amount
in the synovial fluid of CIOA mice. The drug diminishes
the number of RANKL positive CD3 T cells in the syno-
vial extract and changes their RANKL expression.
Reduced TGF-b3a n dp S M A D - 2s i g n a l i n gi ng l u c o s a -
mine-treated mice are in favor of inhibited bone remodel-
ing and formation of BMP-2 positive osteophytes. The
substance is able to limit the excessive bone formation at
the late stage of disease by increased expression of DKK-
1 in the CIOA joints. The data show that glucosamine
ameliorates CIOA progression by regulating the degree of
bone resorption and bone remodeling.
Additional material
Additional file 1: Figure S1. Administration of glucosamine in
severe CIOA. ICR mice were injected with high dose of collagenase (two
i.a. injections with 2 U/mouse at Day 0 and Day 2). After 7 days
glucosamine hydrochloride was administered orally at a dose of 20 mg/
kg for 20 days. (a) Representative joint sections stained with H&E
showed a mild effect of glucosamine on osteophyte formation and bone
remodeling at Day 30 of severe CIOA. (b) Histological score of CIOA
joints was not significantly affected by glucosamine. The data are
expressed as the mean ± SD from two independent experiments
involving five mice per group.
Additional file 2: Figure S2. Effect of glucosamine on osteoclast
differentiation in vitro. Bone marrow cells from healthy mice were
isolated, resuspended at 1 × 10
6/ml in MEM medium (Lonza, Verviers,
Belgium) containing 10% FCS and 50 ng/ml of macrophage colony-
stimulating factor and cultured for one day. Osteoclasts were generated
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macrophage colony-stimulating factor, in the absence or the presence of
increasing concentrations of glucosamine (starting from 5 till 100 μg/ml).
Tartrate-resistant acid phosphatase (TRAP) on osteoclasts was determined
by TRAP staining kit (Sigma-Diagnostics, Charleston, WV, USA). The
number of TRAP-positive cells was counted and the data are expressed
as the mean ± SD from three independent experiments.
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